4,901 trials
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs) — 8; 4; 3; 8 Participants
Nicotine Dependence · Opiate Dependence
Primary: Number of Participants Who Experienced Seven-day Point Prevalence Smoking Abstinence — 3; 0 Participants
Lymphoma, Follicular
Primary: Area Under the Concentration (AUC) Time Curve of BI 695500 and Rituximab (MabThera®) Over the First Dosing Interval (Pre-infusion on Day 1 to Pre-infusion on Day 8)…
Focus of Study of Healthy Adults
Primary: Peak Plasma Nitrate Concentration Over 24 Hour Study Period — 769; 41 microMolar (microM)
Hypertension
Primary: Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Hydrochlorothiazide and Amiloride Hydrochloride — 2160; 2360…
Melanoma
Primary: Number of Patients With Dose-limiting Toxicity (Phase I) — 0; 1; 1; 0 Participants
HIV
Primary: Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events — 7; 1 Adverse events
Asthma · Cockroach Hypersensitivity
Primary: Cumulative Proportion of Participants Meeting Either a Total Nasal Symptom Score (TNSS) Threshold or Sneezing Score Threshold During the Cockroach Allergen (CA) Nasal…
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 16; 10; 0; 0 Participants
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Alectinib — 107; 83.6; 85.5; 85.1 nanograms per milliliter (ng/mL)
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 0; 0 Participants
Respiratory Synctial Virus Infections
Primary: Number of Subjects With Solicited Local Symptoms — 2; 23; 1; 15 Participants
Schizophrenia
Primary: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores (Cohorts 1 and 2) at Day 10 — -0.2; -0.3; 0.1; 0.0 Units on a scale
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 14.9; 23.4; 12.9; 14.0 ng/mL
Uveitis · Intermediate Uveitis · Posterior Uveitis
Primary: Number of Participants With at Least 2-step Decrease in Vitreous Haze (VH) — 4; 4 participants